A series of trials for the combination could "potentially provide a chemotherapy-free treatment option" for patients whose Hodgkin lymphoma either relapsed or can't be treated with surgery.
Monday, June 19, 2017
Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY): Hodgkin lymphoma positive results
Seattle Genetics (SGEN) and Bristol-Myers Squibb (BMY) unveiled strong data for a combination of their drugs Adcetris and Opdivo in classical Hodgkin lymphoma. All signs of cancer disappeared in 63% of patients.
A series of trials for the combination could "potentially provide a chemotherapy-free treatment option" for patients whose Hodgkin lymphoma either relapsed or can't be treated with surgery.
A series of trials for the combination could "potentially provide a chemotherapy-free treatment option" for patients whose Hodgkin lymphoma either relapsed or can't be treated with surgery.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment